Krystal Biotech, Inc.

Valuation Analysis

About the Company

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency

Krystal Biotech, Inc. Stock at a Glance

Krystal Biotech, Inc. (KRYS) is currently trading at $317.97 with a market capitalization of $9.4B. The trailing P/E ratio stands at 42.57x, with a forward P/E of 31.54x. The 52-week range spans from $127.99 to $331.49; the current price is 4.1% below the yearly high. Year-over-year revenue growth stands at +31.9%. The net profit margin stands at 53.92%.

💰 Dividend

Krystal Biotech, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

9 analysts rate Krystal Biotech, Inc. (KRYS) on consensus: Strong Buy. The average price target is $322.78, implying +1.51% from the current price. Analyst price targets range from $241.00 to $399.00.

Krystal Biotech, Inc.: The Investment Case in Detail

Krystal Biotech, Inc. (KRYS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 31.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 94.17%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 53.92%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Short interest sits at 17.53% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 47.43x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 31.54x is meaningfully below the trailing 42.57x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 93.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (17.53%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Krystal Biotech, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.